CEO J.D. Finley promised that the biotech is “in the midst of encouraging discussions that we believe will lead to pipeline expansion opportunities in high value indications in the GI space.” ...

It was an extremely busy week in the biotech sector, with several companies ... The acquisition adds to GSK’s growing portfolio in gastrointestinal (GI) cancers, including ongoing trials with ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Discover outperforming stocks and invest smarter with ...

After a rough start to the year, biotech stocks have been on an upswing, standing out in a difficult market for high-growth stocks. These notoriously volatile names have outperformed the broad ...

The reason for the stock's rapid ascent is a mystery. Biotech stocks can be incredibly attractive for risk-taking investors because of their ability to go parabolic in an instant. Whether it's a ...

So if you're looking to make a relatively small investment of $1,000 in one stock that's on the riskier side, it's hard to park your cash in a more exciting and upwardly mobile biotech than Viking.

Investors' deep pessimism is actually bullish, and less regulatory constraint could fuel new drug approval and M&A Biotech is one of the U.S. stock market's most unloved sectors. But several ...

and there are still more than 100 biotech stocks worth less than the cash they have in the bank. Yet there are also very clear signs that the worst might be over for the sector. For investors with ...

However, investors were disappointed and the stock fell following the announcement ... to GSK’s growing portfolio in gastrointestinal (GI) cancers, including ongoing trials with dostarlimab ...